April 3, 2012 — Adding the targeted agent cetuximab (Erbitux, Bristol-Myers Squibb) to the current standard mFOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimen in patients with ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed no differences in recurrence after endoscopic local resection of low- or high-risk CRC ...

PURPOSE: We generated an anti-idiotype antibody, designated CeaVac, that is an internal image of the carcinoembryonic antigen (CEA). We previously demonstrated that the majority of patients with ...

AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer.

Please provide your email address to receive an email when new articles are posted on . Patients who had detectable ctDNA after resection of stage II colon cancer did not benefit from adjuvant ...

Objective We determined if postoperative physical activity prevents or delays cancer recurrence in patients with stage III colon cancer. Methods This cohort study nested within a randomised trial ...

(HealthDay News) – Adding cetuximab to adjuvant chemotherapy does not improve disease-free survival in stage III colon cancer patients following surgical resection, according to a study published in ...

An estimated 945,000 new cases of colorectal cancer are diagnosed each year, of which approximately 40% will be nonmetastatic lymph node-positive (stage III) disease, and 15–20% will be T3–T4 disease ...

Patients with stage 3 colon cancer who reported physical activity after surgical resection may derive a survival benefit and may prolong disease recurrence. An exercise regimen after surgery may ...

Celebrex improved DFS in ctDNA-positive colon cancer patients, reducing cancer recurrence and death risk by 37% compared to placebo. ctDNA status post-surgery was highly prognostic of DFS and OS, ...

A 3-year structured exercise program post-chemotherapy improved disease-free and overall survival in stage III or high-risk stage II colon cancer patients. Patients in the exercise program reported ...